Lupin Gets Warning Letter From US Health Regulator For Somerset Facility

Drug firm Lupin on Sunday said it has received a warning letter from the US health regulator for its Somerset facility in the US.

The United States Food and Drug Administration (USFDA) had inspected the company's Somerset, New Jersey, facility from September 10, 2020, to November 5, 2020, Lupin said in a regulatory filing.

"The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility," it added.

Lupin is committed to addressing the concerns raised by the USFDA and will work with the FDA and the New Jersey district to resolve these issues at the earliest, the filing said.

"We uphold quality and compliance issues with utmost importance and are committed to be compliant with 'good manufacturing practice' standards across all our facilities," it added.

When USFDA finds that a manufacturer has significantly violated FDA regulations, it notifies the manufacturer. This notification is often in the form of a warning letter.

Earlier, in November 2020, Lupin in a regulatory filing had said that the USFDA had issued 13 observations after the inspection of its subsidiary's Somerset facility.

The company had said that it was confident of addressing these observations and would work closely with the agency to address their concerns.

The facility contributes less than 5 per cent of the company's global revenues, Lupin had said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor